RxDoctor Payments Data

Stanley Schrem, MD

Cardiovascular Disease · New York, NYNPI 1376612242

Payments from drug & device makers

$883in general payments, 2019–2025

Across 51 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$123
  • Amarin Pharma, Inc.$118
  • Amgen$110
  • Johnson & Johnson$104
  • Pfizer$58
  • Biotronik Inc.$51
  • plus $319 from 11 others

What the payments were for

  • Food & beverage$81592%
  • Education$688%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$883 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$240,494
Medicare patients
428
Services billed
3,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$188,172
Repatha SureclickEvolocumab56$37,460
XareltoRivaroxaban30$28,504
OzempicSemaglutide24$24,386
MounjaroTirzepatide22$20,594
EntrestoSacubitril/Valsartan30$19,022
FarxigaDapagliflozin Propanediol29$16,618
LivaloPitavastatin Calcium18$13,396
Praluent PenAlirocumab13$12,041
Ezetimibe286$8,207
Atorvastatin Calcium647$7,481
Rosuvastatin Calcium366$5,150
Metoprolol Succinate287$4,419
Losartan Potassium246$3,644
SynthroidLevothyroxine Sodium40$3,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$188,172248 claims
Johnson & JohnsonXarelto$104$28,50430 claims
Novo NordiskOzempic$33$24,38624 claims
AbbVieSynthroid$46$3,29440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →